BS_7327SDAQ
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 2.463863337713535
- age_years
- 3.896
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.527
- G2M_CHECKPOINT+0.514
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.366
- HEDGEHOG_SIGNALING+0.359
- MYC_TARGETS_V1+0.357
- PROTEIN_SECRETION+0.330
- TGF_BETA_SIGNALING+0.319
- ANGIOGENESIS+0.316
- HYPOXIA+0.310
- COAGULATION+0.304
Top 10 suppressed
- BILE_ACID_METABOLISM-0.268
- KRAS_SIGNALING_DN-0.093
- P53_PATHWAY-0.061
- PEROXISOME-0.059
- HEME_METABOLISM-0.029
- CHOLESTEROL_HOMEOSTASIS+0.002
- FATTY_ACID_METABOLISM+0.008
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.009
- XENOBIOTIC_METABOLISM+0.009
- INTERFERON_GAMMA_RESPONSE+0.014
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.878 |
| 2 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.861 |
| 3 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.858 |
| 4 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.853 |
| 5 | 6AF1465C-7A6C-4AAF-AFF2-3065EA5B7D0B | — | — | 0.850 |
| 6 | SRR934963 | — | — | 0.848 |
| 7 | C3N-00211 | — | cohortSQ1 | 0.841 |
| 8 | BS_23QW0BBA | high-grade glioma | — | 0.839 |
| 9 | C3L-04391 | — | cohortSQ1 | 0.833 |
| 10 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.527 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.514 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.366 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.359 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.357 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.319 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.316 | Remibrutinib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.304 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.284 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.284 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.214 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.204 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.199 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.196 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.191 | Inavolisib | — uncovered |